Search - tctmd.com

Displaying 21 - 40 of 68

Sort: Relevancy | Date

News Conference News AHA 2018

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

Michael O'Riordan

November 14, 2018

New-Generation DES Better Than Older Stents Over 10 Years, Regardless of Polymer Type

News Conference News AHA 2018

New-Generation DES Better Than Older Stents Over 10 Years, Regardless of Polymer Type

November 12, 2018

T-Time: Alteplase Infusion No Help for Failed Reperfusion in STEMI PCI

News Conference News AHA 2018

T-Time: Alteplase Infusion No Help for Failed Reperfusion in STEMI PCI

November 11, 2018

RE-DUAL PCI Findings Consistent Across Key Subgroups

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

November 16, 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

News Conference News AHA 2017

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

November 14, 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

News Conference News AHA 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Michael O'Riordan

November 12, 2017

News Conference News AHA 2016

Incomplete Revascularization Linked With Increased MACE in Subsequent Noncardiac Surgery

Michael O'Riordan

November 15, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

November 14, 2016

News Conference News AHA 2016

AHA/ACC Issue Updated PAD Guidelines

November 14, 2016

News Conference News AHA 2015

IVUS Tops Angiography for Guiding DES Implantation in Long Lesions

November 09, 2015

News Conference News AHA 2015

DAPT Score Provides ‘Personalized Medicine’ Tool for Determining Whether to Extend Therapy Beyond 1 Year

Yael L. Maxwell

November 09, 2015

News Conference News AHA 2015

Inappropriate PCIs Slashed by Half Since First AUC Released, But Key Questions Remain

November 08, 2015

News Conference News AHA 2014

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

November 18, 2014

News Conference News AHA 2014

Registry: Newer P2Y12 Inhibitors Reduce Stent Thrombosis, Mortality Over Clopidogrel

Yael L. Maxwell

November 17, 2014

News Conference News AHA 2014

Novel, Efficient CT-based FFR Outperforms CTA

November 17, 2014

Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent

Presentation AHA 2014

Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent

Presenter: Dean J. Kereiakes

November 16, 2014

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial

Presentation AHA 2014

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial

Presenter: C.Kaiser

November 16, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.